Gary, I really don't know to what extent IFR's would be available to fund
other non GBM cancer indications because I believe once the public is
aware of such treatments, the number of requests for RFI's could be overwhelming.
I suspect that initially most of those treatments will be funded by wealthy patients
or charitable contributions whereas the treatments of a number of poorer patients
will be funded via IFR.
I would agree that it is logical that once enough positive data is collected from
individual patients and from a small clinical trial (if necessary), the treatment will
most likely be bankrolled by IFR.
I may be wrong but this is just my hunch.
Bullish
Market Data 
Markets 
AI
